InvestorsHub Logo
Followers 18
Posts 932
Boards Moderated 0
Alias Born 04/26/2016

Re: None

Thursday, 04/06/2017 6:01:02 PM

Thursday, April 06, 2017 6:01:02 PM

Post# of 17454
A couple things to note...

First, really happy to see them move the primary endpoint to 52 weeks which was what I expected but it hasn't been confirmed until now. The importance of this can't be underestimated because when they moved from 24wk to 48wk the P-value went from .46 to .001 which is HUGE!!

Second, Great news regarding EU & Japan.

Third, trial criteria remains the same as Ph2b & Aurion. So everyone is aware and you're not caught off-guard by BS Bear rhetoric...they were hoping to move the UPCR requirement from .5 to .7, but it doesn't look like that's happening. This would've been an easier endpoint, but NOTE, they are going with the exact same endpoints of the earlier studies.

And the last point, which we all know...NO BIOPSY CONFIRMATION!

Let's get this thing moving again!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News